ArticleEuropean journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery2025
AMPREDICT MoRe: Predicting Mortality and Re-amputation Risk after Dysvascular Amputation.
Article in European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AMPREDICT Mobility-4: A Novel Four Category Mobility Outcome Prediction Model for Patients Undergoing Vascular Amputation.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to create a novel prediction model (AMPREDICT MoRe) that predicts death and re-amputation after dysvascular amputation, which overcomes prior implementation barriers by using only predictors that are readily available in the electronic health record (EHR).
methodsThis was a retrospective cohort study of 9 221 patients with incident unilateral transmetatarsal, transtibial, or transfemoral amputation secondary to diabetes and or peripheral arterial disease identified in the Veterans Affairs Corporate Data Warehouse between 1 October 2015 and 30 September 2021. The prediction model evaluated factors falling into several key domains: prior revascularisation; amputation level; demographics; comorbidities; mental health; health behaviours; laboratory values; and medications. The primary outcome included four categories: (i) no death and no re-amputation (ND/NR); (ii) no death and re-amputation (ND/R); (iii) death and no re-amputation (D/NR); and (iv) death and re-amputation (D/R). Multinomial logistic regression was used to fit one year post-incident amputation risk prediction models. Variable selection was performed using LASSO (least absolute shrinkage and selection operator), a machine learning methodology. Model development was performed using a randomly selected 80% of the data, and the final model was externally validated using the remaining 20% of subjects.
resultsThe final prediction model included 23 predictors. The following outcome distribution was observed in the development sample: ND/NR, n = 4 254 (57.7%); ND/R, n = 1 690 (22.9%); D/NR, n = 1 056 (14.3%); and D/R, n = 376 (5.1%). The overall discrimination of the model was moderately strong (M index 0.70), but a deeper look at the c indices indicated that the model had better ability to predict death than re-amputation (ND/NR vs. ND/R, 0.64; ND/NR vs. D/NR, 0.78; grouped ND vs. D, 0.79 and NR vs. R, 0.67). The model was best at distinguishing individuals with no negative outcomes vs. both negative outcomes (ND/NR vs. D/R, 0.82).
conclusionThe AMPREDICT MoRe model has been successfully developed and validated, and can be applied at the time of amputation level decision making. Since all predictors are available in the EHR, a future decision support tool will not require patient interview.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.